Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Last trade$12.75
Day change-$0.17 (-1.32%)
Day range$12.53 – $13.03
Volume79,287
Market cap$173M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$173.07M
Price / earnings
—
Price / book
1.26×
Price / sales
1.4×
EV / sales
1.04×
EV / EBITDA
41.74×
Profitability
Earnings per share
-$0.13
Return on assets
-0.93%
Return on equity
-1.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.86×
Quick ratio
2.72×
Cash ratio
1.68×
Cash flow
Price / cash flow
23.12×
Price / free cash flow
75.41×
Free cash flow
$2.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANIK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$30.59M
$32.61M
$29.61M
$30.62M
$27.82M
$28.22M
$26.17M
$30.6M
Cost of revenue
$11.76M
$11.37M
$10.62M
$11.44M
$12.23M
$13.86M
$11.49M
$13.48M
Gross profit
$18.84M
$21.24M
$19M
$19.18M
$15.58M
$14.36M
$14.68M
$17.13M
Selling, general and administrative
$11.65M
$10.95M
$17.77M
$12.08M
$11.87M
$12.23M
$12.91M
$11.32M
Research and development
$7.9M
$7.34M
$6.71M
$6.45M
$6.95M
$6.31M
$6.06M
$6.51M
Total operating expenses
$19.55M
$18.29M
$24.49M
$18.53M
$18.82M
$18.54M
$18.97M
$17.83M
Operating income
-$712K
$2.95M
-$5.49M
$646K
-$3.23M
-$4.18M
-$4.28M
-$705K
Interest expense
$390K
$426K
$0
$0
$997K
$214K
$0
$0
Income before taxes
-$322K
$3.38M
-$4.82M
$764K
-$2.24M
-$3.97M
-$3.87M
$39K
Income taxes
-$11K
$71K
$235K
-$1.04M
$939K
$681K
$89K
$2.53M
Net income
-$311K
$3.31M
-$5.06M
$292K
-$2.33M
-$3.97M
-$4.87M
-$21.87M
Net income attributable to common shareholders
-$311K
$3.31M
-$5.06M
$292K
-$2.33M
-$3.97M
-$4.87M
-$21.87M
EBITDA
$727K
$4.46M
-$4.08M
$1.96M
-$1.83M
-$2.76M
-$2.69M
$1.11M
Basic earnings per share
-$0.02
$0.25
-$0.37
$0.02
-$0.16
-$0.28
-$0.34
-$1.50
Diluted earnings per share
-$0.02
$0.24
-$0.37
$0.02
-$0.16
-$0.28
-$0.34
-$1.50
Recent news
Company coverage with links to the original publishers.
Anika Therapeutics reported Q3 2026 earnings of $0.29 per share, beating consensus estimates of $0.17 by 70.59%, with revenues of $30.59 million exceeding expectations by 3.94%. The stock has gained 101.1% year-to-date, significantly outperforming the S&P 500's 7.4% gain. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
GSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.
Teva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.
Anika Therapeutics granted 3,360 restricted stock units to a newly hired non-executive employee on June 1, 2026, as part of their employment compensation package. The RSUs will vest in three equal installments over three years, subject to continuous service.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.